Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.33 |
| ▸ | HTR3B | O95264 | 1/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.33 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18653324 | 0.81 | HTR3E (0.35) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL16471300 | 0.79 | — | — | |
| SCHEMBL16022924 | 0.78 | HTR3E (0.38) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL16471302 | 0.78 | HTR3E (0.38) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL19069880 | 0.75 | HTR3E (0.38) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL15559750 | 0.74 | HTR3E (0.35) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL16471303 | 0.72 | HTR3E (0.40) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL16471297 | 0.70 | KMT2A (0.33) | — | |
| SCHEMBL17403485 | 0.69 | AHR (0.35) | — | |
| SCHEMBL17212133 | 0.69 | KMT2A (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9693997-B2 | Antiviral compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9540345-B2 | Antiviral compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20160000760-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2016-01-07 | — | — | US | disclosed |
| US-20150368228-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368228-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | HTR3E 4034/4885HTR3B 3432/4885HTR3A 4026/4885 |
| US-20160000760-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | HTR3E 3876/4885HTR3B 3302/4885HTR3A 4004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.